|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
Impact: FDA User Fees, Drug Competition and Pricing — An Inside View
User fees affect drug competition at every level. And user fees are a hot topic during the current budget cycle.
Even as you read this, top-level meetings are under way at the FDA, the White House and in Congress. Policy is being hammered out amid great uncertainty under a new FDA administrator, Scott Gottlieb and a new White House that boasts no special background in drug policy or regulation.
If you plan to remain competitive, it’s time to get up to speed.
Washington insiders Alex Brill and Nancy Bradish Myers Esq. share insights, make forecasts, and help you deal with a fast-changing regulatory and policy landscape. You’ll gain an understanding of:
The Washington landscape is changing fast. Stay competitive! Discover what you need to know now.
Meet Your Presenters
Alex Brill, CEO, Matrix Global Advisors. Prior to entering the private sector, Mr. Brill served as policy director and chief economist to the House Committee on Ways and Means Committee during the Bush II years, helping develop policy on taxes, health, pension, and trade. Previously he served at the White House Council of Economic Advisers. He is a Research Fellow at the American Enterprise Institute.
Nancy Bradish Myers, President, Catalyst Healthcare Consulting Inc., is a Washington-based attorney with deep expertise in health care law, regulation, policy development, government relations and strategic positioning. She previously held senior roles at the FDA, on Capitol Hill, at several trade associations and with investors.
Copyright ©2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing